Recently Featured

Liberate Bio gains licences for myeloid-specific CAR design patents

March 25, 2026
Liberate Bio has secured both exclusive and non-exclusive licenses for patents concerning CAR designs specifically engineered for myeloid cells, including monocytes and macrophages. This strategic move positions the company at the forefront of advancing cell therapy applications targeting these critical immune cells. The significance of myeloid cells in immunotherapy has gained increasing recognition, as they…

Kyowa Ends OX40 Program Amid New Cancer Cases; Sanofi Licenses First-in-Class Drug; BioNTech Advances Duality ADC

March 25, 2026
Kyowa Kirin has announced the termination of its clinical development program for the OX40 drug following the emergence of two new cancer cases. This decision underscores the heightened scrutiny and regulatory challenges that biopharmaceutical companies face in the oncology space, particularly as safety concerns can significantly impact drug development timelines and investor confidence. The implications…

Degenerating Tanycytes Disrupt Tau Removal, Shaping Alzheimer’s Progression

March 25, 2026
Tau-clearing cells in the brain may offer new clues to slowing Alzheimer’s disease progression, according to a study titled “Tanycytic degeneration impairs tau clearance and contributes to Alzheimer’s disease pathology,” from Kyoto University and INSERM, published in Cell Press Blue. The work identifies a previously unrecognized mechanism by which the tau protein accumulates in the…

Bispecific Antibodies Market Predicted to Grow Over 44% by 2030

March 25, 2026
The past few years have seen a striking upward trend in regulatory approvals and industry investment for bispecific antibodies (BsAbs). The global BsAb market is predicted to grow at a CAGR of over 44% through 2030. A recent article in Nature highlighted them as accounting for a quarter of the top 20 highest-grossing deals in…

Ongoing Cases